Abivax (STU:2X1) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2X1 Abivax SA STU:2X1
37 GF Score
Price €122.30
! 2 Warning Signs
View Full Analysis

What is Abivax Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:2X1 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Abivax's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Short Interest distribution charts can be found below:

* The bar in red indicates where Abivax's Short Interest falls into.


STU:2X1
37GF Score
Abivax SA STU:2X1
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
37GF Score

Get the complete analysis for STU:2X1

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€122.30
Price